When: Verified reversal at $170-$172 with MACD turning positive

Then: Add additional 25 bps position

When: $185 close on volume >6M AND MACD histogram positive

Then: Upgrade rating to Overweight

When: Earnings confirming recovery with bookings inflection >5% YoY AND operating margin ≥16.5%

Then: Upgrade rating to Overweight

When: Forward EPS cut >5% from $14.67 consensus, OR break below $170 with follow-through, OR close below $153.90 (50 SMA)

Then: Downgrade to Underweight

HOLD - wait for pullback to $170-$172 zone before building position; cap starter at 25 bps; no scaling until after late September earnings; tighten stop to daily close below $172

• Current $181.38 is not a dip but a 51.5% recovery rally; true support cluster at $170-$172, not aggressive analyst's $176.50 limit
• MACD bearish divergence: price made new high near $186.93 while MACD did not confirm; histogram at -0.01 is the setup preceding bearish re-cross
• RSI rolled over from 75-80 zone and failed to confirm August price highs; momentum stack deteriorating
• Forward P/E of 12.4x based on 17% EPS growth estimate, which requires margin expansion or buybacks beyond current proven levels
• DCF shows overvalued; cheap P/E depends on growth assumptions that may not hold if ACN delivers 10% instead of 17% EPS growth
• Goodwill of $27.8 billion represents 40% of $68.8 billion total assets; vulnerable to impairment in soft consulting demand
• 87% probability of no Fed cuts creates late-cycle tightening environment historically adverse for IT services spending
• Options market wide implied outcome dispersion reflects institutional uncertainty ahead of earnings; not just dealer mechanics
• Downside scenario to 50 SMA at $153.90 represents 15% drawdown with more visible catalysts than upside to 200 SMA at $201.73

→ vs aggressive: Limit entry at $176.50 is above structural support at $170-$172; risking $6.50 to unclear reward with stock at late-stage recovery

→ vs aggressive: MACD convergence at +7.81 vs +7.82 is not noise; it is the precise setup for bearish re-cross after 51.5% rally

→ vs aggressive: Cannot elevate forward P/E to 'real' while demoting DCF to 'assumption' when both use same analyst EPS estimates

→ vs aggressive: 17% EPS growth requires acceleration from mid-single-digit revenue growth; gap must come from unproven margin expansion or finite buybacks

→ vs aggressive: No Fed cuts means higher discount rate applied to earnings; earnings compounding into contracting multiple is not same outcome

→ vs aggressive: McCoy tuck-in adds to $27.8B goodwill pile (40% of assets); integration risk is small but non-zero in first 12-18 months

→ vs aggressive: ACN's structural discount at 12.4x reflects concerns about consulting model; cannot buy 'bifurcation premium' while ignoring discount cause

→ vs aggressive: Staged entry scaling to 100-150 bps is not disciplined; creates meaningful single-name risk with elevated IV and earnings event ahead

→ vs aggressive: Wide options implied outcome dispersion is information from sophisticated players, not just dealer hedging; changes position sizing into event

HOLD at current $181.38 price; CONDITIONAL BUY at $176.50 for 25 basis points with staged additions up to 50bp maximum through earnings window

• HOLD at current $181.38 close; conditional BUY only near $176.50 support
• First tranche: 25 basis points at $176.50 after $175–$178 support holds into close or produces clear reversal
• Add second 25bp tranche only after price reclaims approximately $172 from the $170–$172 zone
• Total exposure capped at 50 basis points through earnings window
• Daily close below $172 triggers no additional buying and ideally reduces half the starter position
• Weekly close below $170 invalidates tactical trade and eliminates remaining position
• Approach $153.90 requires full thesis reassessment rather than assuming 50-day SMA support
• No additions above $185 unless $185–$186 resistance is closed above with volume near/above 6 million shares, RSI recovering above 62, and MACD histogram turning positive
• Post-earnings increase to 75–100bp only if bookings, AI demand, and forward guidance validate earnings recovery
• Full 100–150bp overweight remains deferred until technical and fundamental evidence improve together
• Fundamental support exists: $1.78B net cash, ~$12.09B trailing FCF, ~$27.8B goodwill, $9.6B capital returns, 3.49% dividend yield
• Valuation at 12.38x forward P/E is reasonable but not guaranteed; 17% EPS estimate depends on buybacks, favorable comparisons, and margin improvement
• 51.5% rebound from June low and 26.7% one-month gain suggest suboptimal entry timing
• 200-day SMA at $201.73 offers ~14.3% upside from $176.50 entry but is not guaranteed fair-value target
• $190.46 upper Bollinger Band is more realistic first upside reference (~7.9% from $176.50)
• 87% probability of no 2026 Fed cuts may cap multiple expansion despite stable demand
• Technical: 10.1% below 200-day SMA, RSI rolling over to 60.62, MACD marginally negative
• Diversification essential; avoid adding if portfolio already has significant IT-services or technology exposure

→ vs aggressive: Overstates fundamental certainty; turns attractive features into guaranteed outcomes; overlooks that trade is being initiated after 51.5% rebound from June low and 26.7% one-month gain

→ vs aggressive: Exaggerates upside: 200-day SMA at $201.73 offers ~14.3% from $176.50, not 20%; is dynamic moving average and currently overhead resistance, not guaranteed fair-value target

→ vs aggressive: Sub-0.75 growth-adjusted multiple is not directly comparable with reported PEG of 1.35; ACN is reasonably valued, not self-evidently cheap

→ vs aggressive: Net cash of $1.78B is meaningful but modest relative to ~$111B market cap; ~$27.8B goodwill (~40% of assets) deserves monitoring

→ vs aggressive: Dismisses macro evidence too readily; higher discount rates can still cap valuation even with stable demand

→ vs aggressive: Wide options-implied outcome range should not be ignored; supports smaller sizing and defined event-risk plan

→ vs conservative: Recommended $170–$172 entry is too rigid when technical report identifies $176.20 Bollinger middle line and $175–$178 as constructive add-on area

→ vs conservative: Proposed daily close below $172 as stop is logically unsuitable for entry at $170–$172 since $172 would be at or above purchase price; cannot function as downside invalidation

→ vs conservative: Too dismissive of valid support entry; refusing to buy at $176.50 if support holds can mean never owning ACN even if thesis is correct

→ vs conservative: 100–150bp single-name overweight is more aggressive than evidence requires, especially with existing tech/consulting/AI exposure, but waiting for perfect confirmation is also not the answer